Health Policy Updates

The Network is thrilled to announce that its 2025 Capitol Brief is now live on LegisLink! Over the last year, The Network’s advocacy efforts have emphasized the value of community oncology to policymakers, setting the stage for Medicare physician pay reform, advancing site neutral payment reform, and addressing anti-competitive hospital behavior.

In an op-ed in MedPage Today, Dr. Amy McNally, The Network’s Chief Surgical Officer, describes how reimbursement for surgical professional services has declined, disproportionately affecting private practices and tipping the scales toward hospital settings

On Friday, November 1, the Centers for Medicare and Medicaid Services (CMS) issued the finalized 2025 Medicare Physician Fee Schedule (PFS) and Quality Payment Program (QPP).

Dr. Moshe Chasky, a hematologist-oncologist at Alliance Cancer Specialists. authored a letter to the editor (LTE) published in STAT on October 26, 202

The House of Representatives passed H.R. 5526, The Seniors’ Access to Critical Medications Act by a voice vote on Monday, September 23, sending the bill over to the Senate for consideration.

The US Oncology Network submitted comments on Friday, August 2 in response to Representatives Dianna DeGette (D-CO) and Larry Bucshon, M.D. (R-IN) request for information on the 21st Century Cures Initiative.

Dr. Moshe Chasky, a hematologist-oncologist at Alliance Cancer Specialists, authored a letter to the editor (LTE) published in The Washington Post on July 27, 2024.

THE WOODLANDS, Texas— The US Oncology Network, a national network of independent physicians delivering value-based, integrated, cancer care in the community setting, today expressed deep concerns with the continued cuts to physician reimbursement in the Medicare Physician Fee Schedule (PFS) Proposed Rule for Calendar Year (CY) 2025.

The Centers for Medicare and Medicaid Services (CMS) issued a proposed rule for the 2025 Medicare Physician Fee Schedule (PFS) and Quality Payment Program (QPP).

The report is part of an ongoing inquiry launched by the FTC in 2022 on PBMs and their impact on access to and affordability of medicines.